Bedrijfsoverzicht
Tango Therapeutics, Inc. is a precision oncology company dedicated to the discovery and development of novel drugs specifically designed for defined patient populations that face significant unmet medical needs. The organization operates within the broader Healthcare sector and the specialized Biotechnology industry, an environment characterized by high innovation rates and substantial regulatory hurdles for bringing new therapies to market. At present, the company holds a market capitalization of $2.85B and employs approximately 137 staff members to drive its research and development initiatives. Although the company reports an annual revenue of $62.38M over the trailing twelve months, the combination of a substantial market cap and relatively modest revenue indicates that the valuation is heavily influenced by the potential value of its development pipeline rather than current cash generation. This disparity between market cap and revenue is typical for biotechnology firms at this stage, where investor confidence is placed on the future commercialization of assets like TNG462 rather than immediate profitability.
Financiële gezondheid
The company reported a revenue of $62.38M for the trailing twelve months, while simultaneously posting a net income of $-101,594,000 and an EBITDA of $-109,008,000. The significant gap between the positive revenue figure and the large negative net income reveals a cost structure where operating expenses, likely dominated by research, development, and clinical trial costs, far exceed total sales income. Free cash flow stands at $-60,859,624, which indicates that the company is currently burning cash to fund its operations and pipeline advancement, limiting immediate financial flexibility without external capital raises. Three distinct margin metrics highlight the financial pressure on the business: the gross margin is -111.9%, the operating margin is -178.4%, and the profit margin is -162.9%. These negative margin levels reflect the capital-intensive nature of biotechnology, where high upfront costs in R&D and clinical testing result in losses before any product reaches market saturation or generates significant sales volume. In terms of solvency, the company holds $343.14M in cash against total debt of $33.57M, resulting in a debt-to-equity ratio of 9.70. Despite the high debt-to-equity figure, the substantial cash reserve suggests a conservative approach to managing short-term obligations rather than aggressive leverage. The current ratio is recorded at 16.32, a figure that indicates exceptionally strong short-term liquidity and the ability to cover current liabilities many times over with available current assets. Finally, the return on equity is -37.2% and the return on assets is -19.5%, metrics that reveal that management has not yet achieved positive returns on the capital invested in the company, a common characteristic for pre-revenue or early-stage biotechnology entities.
Waarderingsbeoordeling
Valuation metrics for Tango Therapeutics present a complex picture due to the lack of positive earnings, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -12.52. The absence of a trailing P/E and the negative forward P/E imply that the market is not valuing the stock based on current or near-term profitability, but rather on speculative growth expectations and pipeline potential. The price-to-book ratio is 7.83, suggesting that the market values the company at a significant premium over its book value, likely reflecting the intangible value of its intellectual property and drug candidates. Alternative valuation multiples such as the price-to-sales ratio of 45.63 and the EV/EBITDA of -23.27 further illustrate that traditional earnings-based valuation models are not applicable, as these high multiples indicate investors are willing to pay substantial amounts per dollar of sales despite current losses. Regarding trading ranges, the 52-week high is $22.20 and the 52-week low is $1.03, meaning the current price sits somewhere within this wide historical volatility band. The beta value of 1.31 indicates that the stock price tends to be more volatile than the broader market, moving 31% more than the market average during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is recorded at -100.0%, while earnings growth year-over-year is N/A, indicating a complete contraction in reported revenue compared to the prior period. Since earnings growth is not calculable due to the negative earnings baseline, the decline in revenue reflects a specific contraction in sales rather than a divergence between earnings and revenue trajectories. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the firm retains all earnings and reinvests capital directly into research, development, and clinical trials rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology companies focused on long-term pipeline development rather than immediate shareholder returns. Consequently, the overall growth and income profile is defined by a complete lack of current revenue growth and an absence of dividend income, with value derived entirely from the potential future success of its drug candidates.